A5011277242- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Nanowire Synthesis and Applications
- Virus-based gene therapy research
- Monoclonal and Polyclonal Antibodies Research
- Advanced biosensing and bioanalysis techniques
- Cancer Research and Treatments
- Viral Infectious Diseases and Gene Expression in Insects
- Cancer Immunotherapy and Biomarkers
- Biosimilars and Bioanalytical Methods
- Silicon Carbide Semiconductor Technologies
- Advancements in Semiconductor Devices and Circuit Design
- Immune Cell Function and Interaction
Center for Integrated Protein Science Munich
2018-2021
Ludwig-Maximilians-Universität München
2018-2021
German Center for Lung Research
2018-2021
München Klinik
2020
LMU Klinikum
2019
The combination of directed migration and immunosuppressive shielding enables effective T cell therapy in solid tumors.
CD16-chimeric antigen receptors (CAR) T cells recognise the Fc-portion of therapeutic antibodies, which can enable selective targeting different antigens. Limited evidence exists as to CD16-CAR design and antibody partner might be most effective. We have hypothesised that use high-affinity CD16 variants, with increased Fc-terminus affinity, combined Fc-engineered would provide superior cell efficacy. (wild-type or variants) were co-cultured Panc-1 pancreatic cancer, Raji lymphoma A375...
Abstract Targeted T cell therapy is highly effective in disease settings where tumor antigens are uniformly expressed on malignant cells and off-tumor on-target-associated toxicity manageable. Although acute myeloid leukemia (AML) has principle been shown to be a cell-sensitive by the graft-versus-leukemia activity of allogeneic stem transplantation, so far failed this setting. This largely due lack target structures both sufficiently selective AML, causing unacceptable toxicity. To address...
<h3>Background</h3> Targeted immunotherapies have shown limited success in the context of acute myeloid leukemia (AML). The mutational landscape, heterogeneity attributed to this malignancy and toxicities associated with targeting lineage antigens, it has become apparent that a modular controllable cell therapy approach potential target multiple antigens is required. We propose controlled ACT approach, where T cells are equipped synthetic agonistic receptors (SARs) selectively activated only...
<h3>Background</h3> Chimeric antigen receptor (CAR) T cell therapy is currently approved for the treatment of some hematological malignancies. However, CAR cells have so far lacked efficacy in solid tumors. A major hurdle limited infiltration into tumor tissue. Chemokine receptors enable immune to migrate along a chemokine gradient. Here, we show that overexpression C-X-C 6 (CXCR6) enhances accumulation motif ligand 16 (CXCL16)-positive xenograft pancreatic cancer models, resulting increased...
<h3>Background</h3> CAR T cell therapy is remarkably successful in patients with hematological malignancies, some cases inducing durable remissions. However, it remains ineffective solid tumors, part due to poor infiltration into the tumor mass. Determinants of site remain be defined. In contrast, tumors actively attract regulatory (T<sub>reg</sub>) cells for immune suppression through C-C chemokine receptor 8 (CCR8) - CCL1 axis. As this axis functional across cancer entities, we postulated...
<h3>Background</h3> Targeted immunotherapies have shown limited success in the context of acute myeloid leukemia (AML). Due to mutational landscape and heterogeneity attributed this malignancy toxicities associated with targeting lineage antigens, it has become apparent that a modular controllable cell therapy approach potential target multiple antigens is required. We propose controlled ACT approach, where T cells are armed synthetic agonistic receptors (SARs) conditionally activated only...
<h3>Background</h3> CAR T cell therapy remains ineffective in solid tumors. Scarce infiltration and suppression at the tumor site are two notable limitations. regulatory (Treg) cells capable of suppressing effective anti-tumor responses through inhibitory factors such as transforming growth factor β (TGF-β). Treg expressing C-C chemokine receptor 8 (CCR8) have been found to accumulate correlate with poor prognosis breast cancer. We postulated that CCR8 could be exploited redirect effector...